Physician profile
Avery E Collins
NPI 1144920281
$6,031.79
in general payments reported to CMS, 2019-2025
23 companies · $2,332 in 2025
The $2,332 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,727 · 2024: $1,973 · 2025: $2,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,559 · Education: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,558.73 |
| Education | $473.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,093.79 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $928.70 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $762.89 | 2023-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $651.94 | 2023-2025 | Ilumya, Odomzo, Blu-U |
| Abbvie INC. | $473.61 | 2023-2025 | |
| Leo Pharma INC. | $445.75 | 2023-2025 | Adbry, Anzupgo |
| Pfizer INC. | $272.77 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $231.24 | 2023-2025 | Libtayo, Dupixent |
| Incyte Corporation | $190.21 | 2023-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $186.68 | 2023-2024 | Sotyktu |
| Genzyme Corporation | $149.48 | 2023-2025 | |
| Dermavant Sciences, INC. | $143.86 | 2023-2024 | Vtama |
| Organogenesis INC. | $99.45 | 2024 | |
| Eli Lilly and Company | $99.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.26 | 2023 | Otezla |
| Galderma Laboratories, L.P. | $51.56 | 2024-2025 | Nemluvio |
| Genentech USA, INC. | $22.46 | 2023 | Erivedge |
| Biofrontera INC. | $21.34 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.52 | 2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $16.03 | 2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.37 | 2024 | Jublia |
| Kerecis Limited | $10.89 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avery Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.